AbbVie (NYSE: ABBV) announced this week a strategic collaboration with US-based Lupus Therapeutics aimed at accelerating the late-stage development of the JAK inhibitor Rinvoq (upadacitinib) for the treatment of systemic lupus erythematosus (SLE). This partnership marks a significant step in expanding the therapeutic applications of Rinvoq, which is already approved for the treatment of seven immune-mediated diseases in the United States.
Collaboration Details
The clinical research affiliate of the non-profit Lupus Research Alliance will support AbbVie in various aspects of an ongoing trial, including patient recruitment, site activation, and engagement. This collaboration will leverage the Lupus Clinical Investigators Network (LuCIN), enhancing the trial’s reach and efficiency in the pursuit of new treatment options for SLE patients.
Rinvoq’s Expanding Therapeutic Portfolio
According to the press release, Rinvoq’s approval for multiple immune-mediated diseases underscores its potential as a versatile therapeutic agent. The collaboration with Lupus Therapeutics is expected to further validate Rinvoq’s efficacy and safety profile in treating SLE, potentially adding another indication to its growing list of approved uses.-Fineline Info & Tech
